Further studies have found that PKM2 plays an important role in PB2 anti-liver cancer effect and enhances liver cancer cell sensitivity to sorafenib.[44] PB2 can inhibit PKM2 nuclear translocation, reduce HIF-1α expression, reduce PKM2/HIF-1α pathway activity, inhibit HIF-1α transcriptional activity, and further reduce the expression of tumor-related genes regulated by HIF-1α such as glycolysis-related enzymes and glucose transporters, thereby inhibiting liver cancer cell proliferation.[44]. This evidence concerns the gene HIF1A and liver cancer.